Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter

Affiliations

• ¹ Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
• ² Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
• ³ SixPeaks Bio, Basel, Switzerland.
• ⁴ Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
• ⁵ Preclinical Sciences and Translational Safety, Janssen Pharmaceutica, Beerse, Belgium.
• ⁶ AutoChem R&D, Mettler-Toledo International, Greifensee, Switzerland.
• ⁷ Independent consultant, Cambridge, Great Britain.
• ⁸ Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
• ⁹ Discovery Microbiology, Aptuit (Verona) Srl, an Evotec Company, Verona, Italy.
• ¹⁰ Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
• ¹¹ Roche Pharma Research and Early Development, Informatics, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
• ¹² Therapeutics Discovery, Janssen Pharmaceutica, Beerse, Belgium.
• ¹³ Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. [email protected].
• ¹⁴ Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland. [email protected].